Establishing and Maintaining an Extensive Library of Patient-Derived Xenograft Models

por Mattar, Marissa, McCarthy, Craig R., Kulick, Amanda R., Qeriqi, Besnik, Guzman, Sean, de Stanchina, Elisa
Publicado 2018

CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma

por Odintsov, Igor, Ortiz, Michael V., Khodos, Inna, Mattar, Marissa S., Lui, Allan J.W., Kohsaka, Shinji, de Stanchina, Elisa, Bender, Julia L. Glade, Ladanyi, Marc, Somwar, Romel
Publicado 2022

LPTO-04. GENERATION AND CHARACTERIZATION OF PATIENT-DERIVED PRECLINICAL MODELS FROM TUMOR CELLS ISOLATED FROM CEREBROSPINAL FLUID

por Offin, Michael, Vojnic, Morana, Liu, Zebing, Lui, Allan, Siau, Evan, Gladstone, Eric, Mattar, Marissa, Khodos, Inna, Drilon, Alexander, Boire, Adrienne, Rudin, Charles, De Stanchina, Elisa, Ladanyi, Marc, Somwar, Romel
Publicado 2019

MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression

por Farnsworth, Dylan A., Inoue, Yusuke, Johnson, Fraser D., de Rappard-Yuswack, Georgia, Lu, Daniel, Shi, Rocky, Ma, Lok In Josephine, Mattar, Marissa S., Somwar, Romel, Ladanyi, Marc, Unni, Arun M., Lockwood, William W.
Publicado 2022

Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer

por Pereira, Patrícia M. R., Mandleywala, Komal, Monette, Sébastien, Lumish, Melissa, Tully, Kathryn M., Panikar, Sandeep Surendra, Cornejo, Mike, Mauguen, Audrey, Ragupathi, Ashwin, Keltee, Nai C., Mattar, Marissa, Janjigian, Yelena Y., Lewis, Jason S.
Publicado 2022

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

por Somwar, Romel, Hofmann, Nicolle E., Smith, Bryan, Odintsov, Igor, Vojnic, Morana, Linkov, Irina, Tam, Ashley, Khodos, Inna, Mattar, Marissa S., de Stanchina, Elisa, Flynn, Daniel, Ladanyi, Marc, Drilon, Alexander, Shinde, Ujwal, Davare, Monika A.
Publicado 2020

Prospective Clinical Genomic Profiling of Ewing Sarcoma: ERF and FGFR1 Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance

por Ogura, Koichi, Elkrief, Arielle, Bowman, Anita S., Koche, Richard P., de Stanchina, Elisa, Benayed, Ryma, Mauguen, Audrey, Mattar, Marissa S., Khodos, Inna, Meyers, Paul A., Healey, John H., Tap, William D., Hameed, Meera, Zehir, Ahmet, Shukla, Neerav, Sawyers, Charles, Bose, Rohit, Slotkin, Emily, Ladanyi, Marc
Publicado 2022

Regenerative lineages and immune-mediated pruning in lung cancer metastasis

por Laughney, Ashley M., Hu, Jing, Campbell, Nathaniel R., Bakhoum, Samuel F., Setty, Manu, Lavallée, Vincent-Philippe, Xie, Yubin, Masilionis, Ignas, Carr, Ambrose J., Kottapalli, Sanjay, Allaj, Viola, Mattar, Marissa, Rekhtman, Natasha, Xavier, Joao B., Mazutis, Linas, Poirier, John T., Rudin, Charles M., Pe’er, Dana, Massagué, Joan
Publicado 2020

RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation

por Hayashi, Takuo, Odintsov, Igor, Smith, Roger S., Ishizawa, Kota, Liu, Allan J. W., Delasos, Lukas, Kurzatkowski, Christopher, Tai, Huichun, Gladstone, Eric, Vojnic, Morana, Kohsaka, Shinji, Suzawa, Ken, Liu, Zebing, Kunte, Siddharth, Mattar, Marissa S., Khodos, Inna, Davare, Monika A., Drilon, Alexander, Cheng, Emily, de Stanchina, Elisa, Ladanyi, Marc, Somwar, Romel
Publicado 2021

Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling

por Smith, Roger S., Odintsov, Igor, Liu, Zebing, Lui, Allan Jo-Weng, Hayashi, Takuo, Vojnic, Morana, Suehara, Yoshiyuki, Delasos, Lukas, Mattar, Marissa S., Hmeljak, Julija, Ramirez, Hillary A., Shaw, Melissa, Bui, Gabrielle, Hartono, Alifiani B., Gladstone, Eric, Kunte, Siddharth, Magnan, Heather, Khodos, Inna, De Stanchina, Elisa, La Quaglia, Michael P., Yao, Jinjuan, Laé, Marick, Lee, Sean B., Spraggon, Lee, Pratilas, Christine A., Ladanyi, Marc, Somwar, Romel
Publicado 2022

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

por Schram, Alison M., Odintsov, Igor, Espinosa-Cotton, Madelyn, Khodos, Inna, Sisso, Whitney J., Mattar, Marissa S., Lui, Allan J.W., Vojnic, Morana, Shameem, Sara H., Chauhan, Thrusha, Torrisi, Jean, Ford, Jim, O'Connor, Marie N., Geuijen, Cecile A.W., Schackmann, Ron C.J., Lammerts van Bueren, Jeroen J., Wasserman, Ernesto, de Stanchina, Elisa, O'Reilly, Eileen M., Ladanyi, Marc, Drilon, Alexander, Somwar, Romel
Publicado 2022

Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation

por Cocco, Emiliano, Schram, Alison M, Kulick, Amanda, Misale, Sandra, Won, Helen H, Yaeger, Rona, Razavi, Pedram, Ptashkin, Ryan, Hechtman, Jaclyn F, Toska, Eneda, Cownie, James, Somwar, Romel, Shifman, Sophie, Mattar, Marissa, Selçuklu, S Duygu, Samoila, Aliaksandra, Guzman, Sean, Tuch, Brian B, Ebata, Kevin, de Stanchina, Elisa, Nagy, Rebecca J, Lanman, Richard B, Houck-Loomis, Brian, Patel, Juber A, Berger, Michael F, Ladanyi, Marc, Hyman, David M, Drilon, Alexander, Scaltriti, Maurizio
Publicado 2019

Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

por Miyazaki, Isao, Odintsov, Igor, Ishida, Keiji, Lui, Allan J. W., Kato, Masanori, Suzuki, Tatsuya, Zhang, Tom, Wakayama, Kentaro, Kurth, Renate I., Cheng, Ryan, Fujita, Hidenori, Delasos, Lukas, Vojnic, Morana, Khodos, Inna, Yamada, Yukari, Ishizawa, Kota, Mattar, Marissa S., Funabashi, Kaoru, Chang, Qing, Ohkubo, Shuichi, Yano, Wakako, Terada, Ryuichiro, Giuliano, Claudio, Lu, Yue Christine, Bonifacio, Annalisa, Kunte, Siddharth, Davare, Monika A., Cheng, Emily H., de Stanchina, Elisa, Lovati, Emanuela, Iwasawa, Yoshikazu, Ladanyi, Marc, Somwar, Romel
Publicado 2023

Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

por Miyazaki, Isao, Odintsov, Igor, Ishida, Keiji, Lui, Allan J. W., Kato, Masanori, Suzuki, Tatsuya, Zhang, Tom, Wakayama, Kentaro, Kurth, Renate I., Cheng, Ryan, Fujita, Hidenori, Delasos, Lukas, Vojnic, Morana, Khodos, Inna, Yamada, Yukari, Ishizawa, Kota, Mattar, Marissa S., Funabashi, Kaoru, Chang, Qing, Ohkubo, Shuichi, Yano, Wakako, Terada, Ryuichiro, Giuliano, Claudio, Lu, Yue Christine, Bonifacio, Annalisa, Kunte, Siddharth, Davare, Monika A., Cheng, Emily H., de Stanchina, Elisa, Lovati, Emanuela, Iwasawa, Yoshikazu, Ladanyi, Marc, Somwar, Romel
Publicado 2023

Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer

por Joshi, Suhasini, Gomes, Erica DaGama, Wang, Tai, Corben, Adriana, Taldone, Tony, Gandu, Srinivasa, Xu, Chao, Sharma, Sahil, Buddaseth, Salma, Yan, Pengrong, Chan, Lon Yin L., Gokce, Askan, Rajasekhar, Vinagolu K., Shrestha, Lisa, Panchal, Palak, Almodovar, Justina, Digwal, Chander S., Rodina, Anna, Merugu, Swathi, Pillarsetty, NagaVaraKishore, Miclea, Vlad, Peter, Radu I., Wang, Wanyan, Ginsberg, Stephen D., Tang, Laura, Mattar, Marissa, de Stanchina, Elisa, Yu, Kenneth H., Lowery, Maeve, Grbovic-Huezo, Olivera, O’Reilly, Eileen M., Janjigian, Yelena, Healey, John H., Jarnagin, William R., Allen, Peter J., Sander, Chris, Erdjument-Bromage, Hediye, Neubert, Thomas A., Leach, Steven D., Chiosis, Gabriela
Publicado 2021